Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment.
10.1007/s13238-017-0394-6
- Author:
Yelei GUO
1
;
Kaichao FENG
2
;
Yao WANG
1
;
Weidong HAN
3
Author Information
1. Molecular & Immunological Department, Chinese PLA General Hospital, Beijing, 100853, China.
2. Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, 100853, China.
3. Molecular & Immunological Department, Chinese PLA General Hospital, Beijing, 100853, China. hanwdrsw69@yahoo.com.
- Publication Type:Journal Article
- Keywords:
cancer stem cells;
chimeric antigen receptor;
immunotherapy;
response evaluation criterion;
translational medicine
- MeSH:
Humans;
Molecular Targeted Therapy;
methods;
Neoplasms;
immunology;
pathology;
therapy;
Neoplastic Stem Cells;
pathology;
Receptors, Chimeric Antigen;
metabolism;
T-Lymphocytes;
immunology;
metabolism;
Translational Medical Research
- From:
Protein & Cell
2018;9(6):516-526
- CountryChina
- Language:English
-
Abstract:
Cancer stem cells (CSCs), a subpopulation of tumor cells, have self-renewal and multi-lineage differentiation abilities that play an important role in cancer initiation, maintenance, and metastasis. An accumulation of evidence indicates that CSCs can cause conventional therapy failure and cancer recurrence because of their treatment resistance and self-regeneration characteristics. Therefore, approaches that specifically and efficiently eliminate CSCs to achieve a durable clinical response are urgently needed. Currently, treatments with chimeric antigen receptor-modified T (CART) cells have shown successful clinical outcomes in patients with hematologic malignancies, and their safety and feasibility in solid tumors was confirmed. In this review, we will discuss in detail the possibility that CART cells inhibit CSCs by specifically targeting their cell surface markers, which will ultimately improve the clinical response for patients with various types of cancer. A number of viewpoints were summarized to promote the application of CSC-targeted CART cells in clinical cancer treatment. This review covers the key aspects of CSC-targeted CART cells against cancers in accordance with the premise of the model, from bench to bedside and back to bench.
